1. Home
  2. GDO vs ANIX Comparison

GDO vs ANIX Comparison

Compare GDO & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Global Corporate Defined Opportunity Fund Inc.

GDO

Western Asset Global Corporate Defined Opportunity Fund Inc.

N/A

Current Price

$9.76

Market Cap

80.2M

Sector

Finance

ML Signal

N/A

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

N/A

Current Price

$2.65

Market Cap

114.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GDO
ANIX
Founded
N/A
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.2M
114.0M
IPO Year
2009
2013

Fundamental Metrics

Financial Performance
Metric
GDO
ANIX
Price
$9.76
$2.65
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.67
AVG Volume (30 Days)
38.8K
325.0K
Earning Date
01-01-0001
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.82
EPS
N/A
N/A
Revenue
N/A
$210,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.90
$2.32
52 Week High
$12.15
$5.46

Technical Indicators

Market Signals
Indicator
GDO
ANIX
Relative Strength Index (RSI) 11.16 28.15
Support Level N/A $2.37
Resistance Level $10.86 $3.09
Average True Range (ATR) 0.06 0.21
MACD -0.03 -0.07
Stochastic Oscillator 0.00 2.75

Price Performance

Historical Comparison
GDO
ANIX

About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.

Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: